CRL
VENTE TOTALE: 69 367 titres (~19 952 667,52 $ US)
- Insiders
- FOSTER JAMES C, Andrews Nancy C, Girshick Birgit
- Total bought
- —
- Total sold
- $19,952,668
- Last activity
- 2026-08-25
- Last synced
-
2026-08-31 10:14:36
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-07
CRL presents a deeply concerning financial profile with deteriorating profitability, a net loss in 2025, and dangerously high leverage (Debt/EBITDA at 6.94), leaving virtually no margin of safety.
The first sentence of the analysis written for CRL on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-27 | 2024-12-28 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 30.5% | 32.9% | 36.4% | 36.8% | 37.7% | |
| Ebit Margin | 0.2% | 5.4% | 17.4% | 17.2% | 15.7% | |
| Ebitda Margin | 10.2% | 14.3% | 25.0% | 24.8% | 23.2% | |
| Operating Profit Margin | 12.6% | 5.6% | 14.9% | 16.4% | 16.7% | |
| Pretax Profit Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | |
| Continuous Operations Profit Margin | -3.5% | 0.6% | 11.6% | 12.4% | 11.3% | |
| Net Profit Margin | -3.6% | 0.3% | 11.5% | 12.2% | 11.0% | |
| Bottom Line Profit Margin | -3.6% | 0.3% | 11.5% | 12.2% | 11.0% | |
| Current Ratio | 1.292 | 1.411 | 1.525 | 1.318 | 1.233 | |
| Quick Ratio | 1.025 | 1.131 | 1.164 | 1.084 | 1.040 | |
| Solvency Ratio | 0.066 | 0.093 | 0.174 | 0.173 | 0.148 | |
| Cash Ratio | 0.191 | 0.196 | 0.262 | 0.214 | 0.237 | |
| Price To Earnings Ratio | -69.986 | 930.800 | 25.502 | 22.769 | 48.492 | |
| Price To Earnings Growth Ratio | 0.045 | -9.513 | -8.135 | 0.983 | 8.486 | |
| Forward Price To Earnings Growth Ratio | 0.045 | -9.513 | -8.135 | 0.983 | 8.486 | |
| Price To Earnings Diluted Ratio | -69.986 | 930.800 | 25.640 | 22.985 | 49.576 | |
| Price To Earnings Diluted Growth Ratio | 0.045 | -9.514 | -9.349 | 0.929 | 8.924 | |
| Price To Book Ratio | 3.190 | 2.763 | 3.367 | 3.720 | 7.476 | |
| Price To Sales Ratio | 2.514 | 2.362 | 2.933 | 2.785 | 5.353 | |
| Price To Free Cash Flow Ratio | 19.468 | 19.068 | 33.145 | 37.544 | 35.617 | |
| Price To Operating Cash Flow Ratio | 13.684 | 13.021 | 17.707 | 17.868 | 24.907 | |
| Debt To Assets Ratio | 0.430 | 0.362 | 0.374 | 0.407 | 0.456 | |
| Debt To Equity Ratio | 0.969 | 0.787 | 0.853 | 1.041 | 1.265 | |
| Debt To Capital Ratio | 0.492 | 0.440 | 0.460 | 0.510 | 0.558 | |
| Long Term Debt To Capital Ratio | 0.446 | 0.393 | 0.424 | 0.476 | 0.535 | |
| Financial Leverage Ratio | 2.255 | 2.175 | 2.278 | 2.554 | 2.771 | |
| Working Capital Turnover Ratio | 10.916 | 8.415 | 9.166 | 13.516 | 11.756 | |
| Operating Cash Flow Ratio | 0.658 | 0.739 | 0.648 | 0.568 | 0.736 | |
| Operating Cash Flow Sales Ratio | 0.184 | 0.181 | 0.166 | 0.156 | 0.215 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.703 | 0.683 | 0.534 | 0.476 | 0.699 | |
| Debt Service Coverage Ratio | 2.190 | 4.065 | 6.812 | 14.433 | 9.975 | |
| Interest Coverage Ratio | 4.745 | 1.800 | 4.515 | 10.979 | 7.981 | |
| Short Term Operating Cash Flow Coverage Ratio | 12.081 | 0.000 | 0.000 | 0.000 | 7,532.663 | |
| Operating Cash Flow Coverage Ratio | 0.241 | 0.270 | 0.223 | 0.200 | 0.237 | |
| Capital Expenditure Coverage Ratio | 3.366 | 3.153 | 2.147 | 1.908 | 3.326 | |
| Dividend Paid And Capex Coverage Ratio | 3.366 | 3.153 | 2.147 | 1.908 | 3.326 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 31.511 | 20.811 | 14.436 | 14.131 | 26.714 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 30.5% | ▼-2.4% | ▼-4.3% |
| Ebit Margin | 0.2% | ▼-5.2% | ▼-11.0% |
| Ebitda Margin | 10.2% | ▼-4.1% | ▼-9.3% |
| Operating Profit Margin | 12.7% | ▲7.0% | ▼-0.6% |
| Pretax Profit Margin | -2.5% | ▼-4.8% | ▼-11.1% |
| Continuous Operations Profit Margin | -3.5% | ▼-4.2% | ▼-10.0% |
| Net Profit Margin | -3.6% | ▼-3.9% | ▼-9.9% |
| Bottom Line Profit Margin | -3.6% | ▼-3.9% | ▼-9.9% |
| Current Ratio | 1.292 | ▼-0.120 | ▼-0.064 |
| Quick Ratio | 1.025 | ▼-0.106 | ▼-0.064 |
| Solvency Ratio | 0.066 | ▼-0.026 | ▼-0.065 |
| Cash Ratio | 0.191 | ▼-0.005 | ▼-0.029 |
| Price To Earnings Ratio | -69.986 | ▼-1000.786 | ▼-261.502 |
| Price To Earnings Growth Ratio | 0.045 | ▲9.558 | ▲1.672 |
| Forward Price To Earnings Growth Ratio | 0.045 | ▲9.558 | ▲1.672 |
| Price To Earnings Diluted Ratio | -69.986 | ▼-1000.786 | ▼-261.789 |
| Price To Earnings Diluted Growth Ratio | 0.045 | ▲9.559 | ▲1.838 |
| Price To Book Ratio | 3.190 | ▲0.426 | ▼-0.913 |
| Price To Sales Ratio | 2.514 | ▲0.152 | ▼-0.675 |
| Price To Free Cash Flow Ratio | 19.468 | ▲0.400 | ▼-9.500 |
| Price To Operating Cash Flow Ratio | 13.684 | ▲0.663 | ▼-3.753 |
| Debt To Assets Ratio | 0.430 | ▲0.068 | ▲0.024 |
| Debt To Equity Ratio | 0.969 | ▲0.182 | ▼-0.014 |
| Debt To Capital Ratio | 0.492 | ▲0.052 | ▼-0.000 |
| Long Term Debt To Capital Ratio | 0.446 | ▲0.053 | ▼-0.009 |
| Financial Leverage Ratio | 2.255 | ▲0.080 | ▼-0.152 |
| Working Capital Turnover Ratio | 10.916 | ▲2.501 | ▲0.162 |
| Operating Cash Flow Ratio | 0.658 | ▼-0.081 | ▼-0.011 |
| Operating Cash Flow Sales Ratio | 0.184 | ▲0.002 | ▲0.003 |
| Free Cash Flow Operating Cash Flow Ratio | 0.703 | ▲0.020 | ▲0.084 |
| Debt Service Coverage Ratio | 2.190 | ▼-1.874 | ▼-5.305 |
| Interest Coverage Ratio | 4.745 | ▲2.945 | ▼-1.259 |
| Short Term Operating Cash Flow Coverage Ratio | 12.081 | ▲12.081 | ▼-1496.868 |
| Operating Cash Flow Coverage Ratio | 0.241 | ▼-0.029 | ▲0.006 |
| Capital Expenditure Coverage Ratio | 3.366 | ▲0.213 | ▲0.586 |
| Dividend Paid And Capex Coverage Ratio | 3.366 | ▲0.213 | ▲0.586 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 31.511 | ▲10.700 | ▲9.990 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.09B | $9.56B | $12.11B | $11.07B | $18.95B | |
| Enterprise value | $12.95B | $12.09B | $14.90B | $13.94B | $21.91B | |
| EV / Sales | 3.22x | 2.99x | 3.61x | 3.50x | 6.19x | |
| EV / Op. cash flow | 17.55x | 16.46x | 21.79x | 22.49x | 28.80x | |
| EV / Free cash flow | 24.97x | 24.11x | 40.78x | 47.25x | 41.18x | |
| EV / EBITDA | 31.51x | 20.81x | 14.44x | 14.13x | 26.71x | |
| Net debt / EBITDA | 6.94x | 4.35x | 2.70x | 2.90x | 3.61x | |
| Current ratio | 1.29x | 1.41x | 1.52x | 1.32x | 1.23x | |
| Income quality | -5.19x | 29.05x | 1.42x | 1.26x | 1.91x | |
| Graham number | — | $17 | $121 | $112 | $94 | |
| Graham net-net | -$61 | -$61 | -$68 | -$72 | -$72 | |
| Tax burden | 145.1% | 11.1% | 81.7% | 78.0% | 81.3% | |
| Interest burden | -1322.1% | 42.4% | 81.0% | 91.3% | 86.7% | |
| Working capital | $326.7M | $409.0M | $553.6M | $347.4M | $240.9M | |
| Invested capital | $5.45B | $6.00B | $6.55B | $6.01B | $5.60B | |
| Return on assets | -2.0% | 0.1% | 5.8% | 6.4% | 5.6% | |
| Operating ROA | 6.9% | 2.9% | 7.8% | 8.9% | 9.4% | |
| Return on tangible assets | -3.6% | 0.3% | 11.2% | 12.8% | 12.0% | |
| Return on equity | -4.6% | 0.3% | 13.2% | 16.3% | 15.4% | |
| Return on invested capital | 8.4% | 0.9% | 7.1% | 7.9% | 8.1% | |
| Return on capital employed | 8.4% | 3.5% | 8.6% | 10.0% | 9.8% | |
| Earnings yield | -1.4% | 0.1% | 3.9% | 4.4% | 2.1% | |
| Free cash flow yield | 5.1% | 5.2% | 3.0% | 2.7% | 2.8% | |
| Capex / Op. cash flow | 29.7% | 31.7% | 46.6% | 52.4% | 30.1% | |
| Capex / Depreciation | 54.3% | 64.4% | 101.4% | 106.9% | 86.2% | |
| Capex / Sales | 5.5% | 5.8% | 7.7% | 8.2% | 6.5% | |
| SG&A / Sales | 18.5% | 18.5% | 18.1% | 16.7% | 17.5% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.8% | 1.7% | 1.7% | 1.9% | 2.0% | |
| Intangibles / Total assets | 43.5% | 47.4% | 48.3% | 50.0% | 53.7% | |
| Days sales outstanding | 64d | 65d | 69d | 69d | 67d | |
| Days payables outstanding | 19d | 19d | 23d | 30d | 33d | |
| Operating cycle | 104d | 102d | 122d | 106d | 100d | |
| Cash conversion cycle | 84d | 84d | 98d | 76d | 67d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+5.5%EV / Sales ▲+8.0%EV / EBITDA ▲+51.4%EV / Op. cash flow ▲+1.086Earnings yield ▼-0.015
Profitability
Return on equity ▼-0.049Return on assets ▼-0.022Return on invested capital ▲+0.074Return on capital employed ▲+0.050Operating ROA ▲+0.040Income quality ▼-34.234Tax burden ▲+1.340
Efficiency
Days sales outstanding ▼-0.536Days payables outstanding ▲+0.623Operating cycle ▲+1.193Cash conversion cycle ▲+0.570Capex / Sales ▼-0.003R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.120Net debt / EBITDA ▲+2.589Working capital ▼-82236000.000Invested capital ▼-547866000.000Intangibles / Total assets ▼-0.039
Change over 5 years
Valuation
Market cap ▼-46.7%EV / Sales ▼-47.9%EV / EBITDA ▲+18.0%EV / Op. cash flow ▼-11.248Earnings yield ▼-0.035
Profitability
Return on equity ▼-0.200Return on assets ▼-0.076Return on invested capital ▲+0.002Return on capital employed ▼-0.014Operating ROA ▼-0.025Income quality ▼-7.096Tax burden ▲+0.637
Efficiency
Days sales outstanding ▼-2.621Days payables outstanding ▼-13.321Operating cycle ▲+3.555Cash conversion cycle ▲+16.876Capex / Sales ▼-0.010R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.058Net debt / EBITDA ▲+3.332Working capital ▲+85824000.000Invested capital ▼-150376000.000Intangibles / Total assets ▼-0.102
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-05-15 | Rob Bresnahan | Sale | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale | $15,001 - $50,000 |
| 2025-05-08 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-04-08 | Rob Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-01-15 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-25 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2022-08-25 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-09-30 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2019-10-08 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2019-10-07 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2018-09-26 | Lamar Smith | Sale (Full) | $1,001 - $15,000 |
| 2018-09-12 | Thomas MacArthur | Purchase | $1,001 - $15,000 |
| 2018-07-26 | Lamar Smith | Sale (Partial) | $1,001 - $15,000 |
Recent news
- 2026-08-27 Wall Street Is Now Backing the Clarity Act. Here''s the Most Likely Scenario for What Happens Next With Crypto. According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.
- 2026-08-24 Great Lakes Advisors LLC Makes New $459,000 Investment in Charles River Laboratories International, Inc. $CRL Great Lakes Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,026 shares of the medical research company''s stock, valued at approximately $459,000. A
- 2026-08-21 CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running? Charles River''s 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
- 2026-08-21 Charles River Gains 88.6% in a Year: What''s Driving the Rally? CRL''s shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.
- 2026-08-20 John Rogers Trims Sphere Entertainment Co (SPHR) -- Stock Still 106% Overvalued on GF Value On June 30, 2026, John Rogers (Trades, Portfolio), through Ariel Investment, LLC, executed a significant reduction in the firm''s position in Sphere Entertainmen
- 2026-08-20 John Rogers Trims Lindblad Expeditions Holdings Inc (LIND) Stake -- Shares Remain Significantly Overvalued on GF Value On June 30, 2026, John Rogers (Trades, Portfolio), through Ariel Investment, LLC, executed a reduction of the firm''s position in Lindblad Expeditions Holdings I
- 2026-08-20 John Rogers Buys Core Laboratories Inc (CLB) -- Shares Look 28% Undervalued on GF Value On June 30, 2026, John Rogers (Trades, Portfolio), founder of Ariel Investment, LLC, increased the firm''s stake in Core Laboratories Inc (NYSE: CLB) by 904,557 s
- 2026-08-20 Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC''s next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC''s next-generation multivalent.
- 2026-08-11 Charles River Laboratories International (NYSE:CRL) CAO Michael Gunnar Knell Sells 6,645 Shares Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) CAO Michael Gunnar Knell sold 6,645 shares of the firm''s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the sale, the chief accounting
- 2026-08-11 Charles River Laboratories International (NYSE:CRL) Sets New 52-Week High – Still a Buy? Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) hit a new 52-week high on Tuesday. The company traded as high as $277.07 and last traded at $276.34, with a volume of 1025310 shares trading hands. The stock had previously closed at $267.49. Analyst Ratings Changes CRL has been the subject